HerbParlor
Elderberry (Sambucus nigra L.)Emerging evidence

Elderberry

Sambucus nigra L.

Overview

At a glance

Elderberry is the fruit of Sambucus nigra, a European elder species in the Adoxaceae family. Human research around colds, influenza and upper respiratory infections is limited and heterogeneous.

Key takeaway

Elderberry is not one standardized intervention: species, plant material (fruit versus flower), preparation and whether the fruit has been properly cooked can materially change both how the evidence should be interpreted and whether a product is safe.

Common uses studied

Common cold prevention and treatment researchInfluenza-related researchUpper respiratory infection researchTraditional food and preserve uses of cooked ripe fruit

Start here

What are you trying to figure out?

Pick the question closest to yours. Each card jumps to the relevant part of this profile or an existing HerbParlor tool — no sponsored rankings, no hidden ordering.

Understand the herbExplore the evidenceUnderstand formsCheck safetyEvaluate a supplementCompare options

Identity

What is this herb?

Family

Adoxaceae

Species

Sambucus nigra L.

Common names

ElderberryEuropean elderBlack elderCommon elder

Plant parts used

Ripe fruit (berry)Flower (elderflower)

Geographic context

Sambucus nigra is native to Europe and parts of Asia and North Africa and is widely naturalized elsewhere.

Identification notes

Only common elder, Sambucus nigra, should be used. Elderberry and elderflower are different plant materials and should not be treated as interchangeable. Other Sambucus species and other elder plant parts are not equivalent and may present different safety considerations.

Background

Traditional context

Traditions

European traditional food and folk use

Historical uses

Cooked ripe fruit as food and preservesTraditional cold and respiratory-season useElderflower as a distinct traditional plant material

Traditional food and folk use provides historical context but does not by itself establish modern clinical efficacy for colds, influenza or any other condition.

Preparations

Forms & preparations

Forms

Cooked ripe fruitFruit extractFruit juice and syrupLozengesCapsules and tabletsStandardized fruit extractCombination productsElderflower (a distinct plant material)

Preparation methods

Cooking or boiling ripe fruitExtractionStandardized extract preparation

What changes between forms

  • Raw or unripe elderberries and other elder plant parts can contain poisonous cyanide-producing substances and should not be consumed raw.
  • Elderberries should be boiled for 15–20 minutes before consumption to address naturally occurring toxic substances.
  • Elderberry fruit and elderflower are different plant materials and should be distinguished on the label.
  • A standardized fruit extract studied in a particular trial should not automatically be assumed equivalent to every elderberry product.

Clinical studies have evaluated different elderberry preparations, including a standardized extract in an air-travel trial. Findings from one preparation should not be generalized to all elderberry products or preparations.

Research

Research Explorer

Each question summarizes what human research has examined, how it was studied, and the main limitations — not a treatment recommendation.

What does the overall human evidence show?

Population

People studied in human elderberry research for colds, influenza and upper respiratory infections.

Intervention

Different elderberry preparations and extracts.

Comparator

Varies by study; commonly placebo or control.

Outcomes studied

Cold occurrenceCold duration and severityInfluenza duration and severityUpper respiratory infection outcomes

Evidence assessment

NCCIH states that human research for colds, influenza and upper respiratory infections is limited, that some preliminary research suggests possible symptom benefit, and that evidence is insufficient for firm conclusions.

Limitations

  • Limited evidence base
  • Heterogeneous preparations and outcomes
  • Small or short-term studies
  • Insufficient evidence for firm conclusions

Sources

Can elderberry prevent or shorten colds?

Population

Participants across five randomized trials included in a systematic review.

Intervention

Elderberry preparations.

Comparator

Placebo or control.

Outcomes studied

Risk of developing a common coldCold durationCold severity

Evidence assessment

The systematic review found that evidence elderberry reduces the risk of developing a common cold was not established. Elderberry may reduce duration or severity of colds, but certainty was low or uncertain.

Limitations

  • Only five randomized trials
  • Low or uncertain certainty
  • Preparation heterogeneity
  • Risk of bias assessed across heterogeneous studies

Sources

Does elderberry reduce influenza duration or severity?

Population

87 emergency-room patients aged 5 and above with PCR-confirmed influenza.

Intervention

Elderberry extract.

Comparator

Placebo.

Outcomes studied

Influenza durationInfluenza severity

Evidence assessment

The randomized, double-blind, placebo-controlled trial found no evidence that elderberry reduced influenza duration or severity. The study was relatively small and explicitly described its findings as conflicting with previous studies.

Limitations

  • Relatively small sample
  • Specific preparation and population
  • Findings conflict with previous studies
  • A single trial does not determine the overall evidence tier

Sources

What did the air-travel cold trial find?

Population

312 economy-class air travellers in a randomized, double-blind, placebo-controlled clinical trial.

Intervention

A standardized elderberry extract.

Comparator

Placebo.

Outcomes studied

Respiratory and cold outcomes

Evidence assessment

The trial studied a standardized elderberry extract and respiratory and cold outcomes. This is preparation-specific evidence and its findings should not be generalized to all elderberry products or preparations.

Limitations

  • Specific standardized extract
  • Specific air-travel population
  • No automatic equivalence across products
  • Preparation-specific rather than class-level evidence

Sources

Is there evidence supporting elderberry for COVID-19?

Population

People considering elderberry for COVID-19.

Intervention

Elderberry preparations.

Comparator

Not established.

Outcomes studied

COVID-19-related outcomes

Evidence assessment

NCCIH states that there is no good evidence supporting elderberry for COVID-19.

Limitations

  • No good evidence for COVID-19
  • Findings from cold and influenza research should not be transferred to COVID-19
  • COVID-19 is a distinct illness

Sources

What does composition and quality research tell us?

Population

European elderberry and other Sambucus nigra subspecies analyzed in a comprehensive review.

Intervention

Plant-material composition analysis.

Comparator

Not applicable.

Outcomes studied

Phenolic compoundsNutrientsCyanogenic glycosides

Evidence assessment

The review describes variation in phenolic compounds, nutrients and cyanogenic glycosides across European elderberry and other Sambucus nigra subspecies. This is product-quality and plant-material context and should not be converted into clinical efficacy.

Limitations

  • Composition is not efficacy
  • Subspecies variation
  • No clinical outcomes assessed
  • Relevant to product-quality differentiation rather than treatment claims

Sources

Latest evidence

Recently published research

Searching Europe PMC…

Looking for recent publications…

These publications are automatically discovered from Europe PMC. They have not necessarily been independently reviewed by HerbParlor and are not automatically incorporated into the evidence assessment.

Evidence

Evidence

Overall human evidence for elderberry is limited and heterogeneous. NCCIH states that human research for colds, influenza and upper respiratory infections is limited and that evidence is insufficient for firm conclusions, and that there is no good evidence supporting elderberry for COVID-19. A 2021 systematic review of five randomized trials found that evidence elderberry reduces the risk of developing a common cold was not established, and that elderberry may reduce cold duration or severity only with low or uncertain certainty. A 2020 randomized, double-blind, placebo-controlled trial in 87 PCR-confirmed influenza patients found no evidence that elderberry reduced influenza duration or severity and described its findings as conflicting with previous studies. A 2016 air-travel trial studied a standardized elderberry extract specifically, demonstrating why its findings should not be generalized to all elderberry products. A 2024 composition review describes variation in phenolic compounds, nutrients and cyanogenic glycosides across Sambucus nigra subspecies and is relevant to product quality rather than clinical efficacy.

Evidence tier

Emerging

Confidence

Overall certainty remains limited because the studies differ in preparation, population, outcome and methods. Individual study findings should be kept distinct from the overall evidence tier and should not be generalized across elderberry products.

Last evidence review

2026-09-16

Where the evidence is strongest

Possible reduction in cold duration or severity with low or uncertain certainty

How to interpret this

Current evidence does not establish elderberry as a proven treatment for colds, influenza, COVID-19 or any other specific condition. The evidence is better described as limited, heterogeneous and preparation-dependent, with a possible low-certainty signal for cold duration or severity and a negative influenza trial. Raw elderberry safety is a separate and important consideration regardless of efficacy.

Automatic evidence update

Since the last editorial review

Checking Europe PMC…
Checking evidence

Checking for publications published since the last editorial evidence review…

This automatic update detects newly published literature; it does not replace HerbParlor's editorial evidence assessment. Review status is an automatic triage signal. Curated HerbParlor evidence is unchanged until editorial review.

Boundaries

What the evidence does NOT establish

Areas with limited evidence

  • Prevention of the common cold
  • Treatment of influenza
  • COVID-19
  • Broad immune-support claims
  • Health uses outside the better-studied respiratory questions

Evidence gaps

  • Larger and longer randomized trials
  • Consistent preparation and outcome definitions
  • Preparation-specific rather than class-level evidence
  • How closely commercial products reproduce studied interventions
  • Composition-to-efficacy translation

Common misconceptions

  • All elderberry supplements are equivalent.
  • Elderberry fruit and elderflower are interchangeable.
  • Raw elderberries are safe to consume.
  • Elderberry has been proven to prevent colds.
  • Elderberry has been proven to treat influenza.
  • There is good evidence supporting elderberry for COVID-19.
  • Evidence from a standardized extract automatically applies to every elderberry product.
  • Immune-support marketing claims establish clinical effectiveness.
  • Chemical composition (phenolics, nutrients) establishes clinical efficacy.
  • Traditional food use establishes modern clinical efficacy.

Safety

Safety & interactions

General considerations

  • Raw or unripe elderberries and other elder plant parts can contain poisonous cyanide-producing substances.
  • Raw elderberries can cause vomiting, diarrhea and abdominal pain.
  • Both mature and immature raw elderberries can contain naturally occurring toxic substances.
  • Elderberries should be boiled for 15–20 minutes before consumption.
  • Only common elder, Sambucus nigra, should be used.
  • Elderflower and elderberry are different plant materials and should be distinguished.
  • Pregnancy and breastfeeding safety information for elderberry is limited.

Contraindications

  • Raw or unripe elderberries and other raw elder plant parts
  • Elder species other than Sambucus nigra

Pregnancy & nursing

  • Safety information during pregnancy is limited.
  • Safety information during breastfeeding is limited.
  • Pregnant or breastfeeding people should discuss use with a qualified healthcare professional.

Medication interactions to be aware of

No clinically important medication interactions are established in the cited sources. Do not infer the absence of a documented interaction means there is no interaction risk; people taking prescription medicines should discuss elderberry use with a healthcare professional.

Condition considerations

  • People considering elderberry for COVID-19 should be aware that there is no good evidence supporting such use.
  • People with symptoms of a respiratory illness that persist or worsen should seek medical advice rather than self-treating with elderberry.

Reported adverse effects

  • Vomiting (from raw elderberry)
  • Diarrhea (from raw elderberry)
  • Abdominal pain (from raw elderberry)

Duration

  • Safety information for longer-term supplement use is limited; the cited sources primarily address short-term use and food-safety preparation.

Talk to a healthcare professional if any apply

  • Pregnancy or breastfeeding
  • Symptoms that persist or worsen despite use for a respiratory illness
  • Consideration of elderberry for COVID-19
  • Use of prescription medicines
  • Any reaction after consuming raw or unripe elderberry
  • Uncertainty about whether a product is Sambucus nigra or has been properly prepared

Products

What changes between products?

Form differences

  • Raw or unripe elderberries and other elder plant parts can contain poisonous cyanide-producing substances and should not be consumed raw.
  • Elderberries should be boiled for 15–20 minutes before consumption to address naturally occurring toxic substances.
  • Elderberry fruit and elderflower are different plant materials and should be distinguished on the label.
  • A standardized fruit extract studied in a particular trial should not automatically be assumed equivalent to every elderberry product.

Form considerations

  • Cooked ripe fruit, fruit extracts and standardized extracts are different preparation descriptions and should not be compared only by headline milligram amount.
  • A product should be compared with the actual preparation used in the relevant research rather than treated as automatically equivalent.

Plant part considerations

  • Check whether the label identifies elderberry fruit or elderflower, because they are different plant materials.
  • Confirm the material is Sambucus nigra rather than another elder species.

Extract considerations

  • Identify whether the product is described as whole fruit, a fruit extract or a standardized extract.
  • Do not infer an extraction ratio or marker concentration when the label does not provide it.

Standardization considerations

  • Record any stated standardization, but do not treat it as proof of clinical equivalence or superiority.
  • Standardization information helps distinguish products but does not by itself establish efficacy.

Evaluation

How to evaluate a supplement

What to check

  • Sambucus nigra species identity
  • Elderberry fruit versus elderflower
  • Whether the fruit has been properly cooked or prepared
  • Whole fruit versus extract versus standardized extract
  • Preparation matching the relevant research
  • Additional ingredients and combination products
  • Identity and contaminant testing where available
  • Batch or lot traceability where available

Serving considerations

  • Compare the labelled serving and preparation with the intervention used in the research without inventing a dosage recommendation.
  • A larger milligram number does not necessarily mean a stronger or better-supported product.

Testing considerations

  • Look for identity and contaminant testing where available.
  • Look for batch or lot traceability where available.

Label transparency

  • The label should identify Sambucus nigra and distinguish elderberry fruit from elderflower.
  • The preparation or extract type should be identifiable where possible.
  • Combination products should clearly disclose their other active ingredients.
  • Immune-support marketing language should not be treated as evidence that the product reproduces a clinically studied intervention.

Categories

Related categories

Explore the HerbParlor categories this herb is grouped under.

Supplements

Related supplements

Sources

Authoritative sources referenced

verifiedLast reviewed 2026-09-16

Sections reviewed

overviewbotanicaltraditionalContextpreparationsresearchevidencesafetyproductEvaluationrelationshipssources

Created the canonical Elderberry Herb Profile v1 with species- and plant-material-aware identity, an explicit raw-berry safety layer, preparation distinctions, evidence boundaries and source-linked research context.

Regulatory sources are included for context only. Regulatory status is not evidence for or against efficacy, and is not a treatment or safety recommendation.

This profile is provided for educational purposes only and is not medical advice. Traditional context and research summaries are distinguished from claims, and nothing here is a treatment recommendation. Always consult a qualified healthcare professional before using any herb, especially if you are pregnant, nursing, take medication, or have a medical condition.